Half-year report · Q2
7716.TEDINET S100WGNK
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥39.2bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥77.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥38.6bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥7.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥8.3bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥6.9bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.3bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.5bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.0bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥10.5bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥8.6bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥7.0bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥153.8bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥158.3bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥156.8bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.5bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥37.1bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥117.3bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥121.2bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥124.0bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥46.6bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.1bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥32.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥35.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.1bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥7.6bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.3bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥599m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥41.84 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.37 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.88 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥41.7 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.06 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥82.63 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 76.0% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥176m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥176m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥2.8bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥9.8bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥9.8bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥66m |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥23.7bn |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥23.5bn |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥176m |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥8.7bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥3.3bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥3.3bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥363m |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥1.3bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥39.4bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥39.2bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥176m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥10.4bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥126m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥126m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥2.8bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥9.9bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥9.9bn |
| jpcrp040300-q2r_E02331-000DCI Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥401m |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥23.5bn |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥23.3bn |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥126m |
| jpcrp040300-q2r_E02331-000Dental Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥3.3bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥3.3bn |
| jpcrp040300-q2r_E02331-000Industrial Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥415m |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E02331-000Surgical Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥38.7bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥38.6bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥126m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 557
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |